Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
Martin KršákSias SchergerMatthew A MillerVincent CobbBrian T MontagueAndrés F Henao MartinezKyle C MolinaPublished in: Therapeutic advances in infectious disease (2024)
The trial was registered as NCT04847921 with clinicaltrials.gov.